Back to top
more

Intuitive Surgical (ISRG)

(Real Time Quote from BATS)

$507.88 USD

507.88
1,041,901

+1.54 (0.30%)

Updated Nov 4, 2024 09:38 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Here's Why You Should Buy Abiomed (ABMD) Stock Right Now

Abiomed's (ABMD) solid Impella product line and the inclusion in the S&P 500 connect make it a lucrative pick.

    Amedisys (AMED) Buys Back 2.4M Shares From KKR, Stock Up

    Amedisys (AMED) works on its strategy to deploy capital in an accretive manner, maintaining low leverage and substantial borrowing capacity for future investment.

      Medtronic's (MDT) CRHF Arm Growth Strong, Rising Costs a Woe

      The gradually stabilizing Cardiac Rhythm & Heart Failure (CRHF) market increases investor confidence in the Medtronic (MDT) stock.

        NuVasive's (NUVA) Global Prospects Solid, Competition Rife

        NuVasive (NUVA) demonstrates strong sales growth across all geographies. Competitive landscape is a concern.

          Here's Why You Should Invest in Stryker (SYK) Stock Now

          Stryker's (SYK) focus on inorganic expansion and stellar Mako performance make the stock an attractive buy.

            Boston Scientific Grows on New Products Amid Recall Issues

            Boston Scientific's (BSX) 2018 guidance raises optimism for the company's near-term prospects.

              Bruker Unveils New Mass-Spectrometry Products, Boosts CALID

              Bruker's (BRKR) mass-spectrometry business within its CALID group rides high on strong sales performances in recent times.

                4 Medical Device Stocks with Solid Potential to Buy Now

                The Medical Device tax suspension spells good times for MedTech bigwigs.

                  Abbott Launches Afinion 2 Analyzer Rapid Test in the U.S.

                  Abbott's (ABT) recently-launched Afinion 2 analyzer system is likely to boost top-line contributions from the Diagnostic division.

                    Illumina (ILMN) Grows on Innovation & Strategic Partnerships

                    Illumina's (ILMN) alliances with Bristol-Myers Squibb and Loxo Oncology to reap positive results in oncology.

                      Here's Why You Should Invest in Baxter International Now

                      Strategic buyouts consistently help Baxter (BAX) gain market traction. Recently, the company completes the consolidation of both RECOTHROM and PREVELEAK.

                        Here's Why You Should Invest in PerkinElmer (PKI) Stock Now

                        PerkinElmer (PKI) gains from stellar Q1 performance; a raised guidance holds promise.

                          Is Intuitive Surgical (ISRG) Stock Outpacing Its Medical Peers This Year?

                          Is Intuitive Surgical, Inc. (ISRG) Outperforming Other Medical Stocks This Year?

                            ResMed's (RMD) HEALTHCAREfirst Buyout to Boost SaaS Business

                            Integration of HEALTHCAREfirst's solutions suite with ResMed's (RMD) SaaS portfolio will help manage the burgeoning population and provide benefits to patients.

                              Nabaparna Bhattacharya headshot

                              US-North Korea Summit Talks Resume: 4 MedTech Stocks to Watch

                              Here we take a look at four leading MedTech players that are gaining from opportunities in the APAC market

                                Intuitive Surgical Commences Direct Operations in India

                                Intuitive Surgical (ISRG) looks to install a broader base of its flagship da Vinci surgical system through distributor Vattikuti in India.

                                  Here's Why You Should Add ResMed (RMD) to Your Portfolio Now

                                  With a view to consistently lead the SDB market and boost the company's sales, ResMed (RMD) sets sights on product development and innovation.

                                    Here's Why STERIS (STE) Stock is a Must Buy at the Moment

                                    STERIS (STE) gains ground on strategic buyouts and divestments.

                                      Myriad Genetics' Planned Counsyl Buyout to Widen Portfolio

                                      Myriad Genetics (MYGN) plans to retain Counsyl as a wholly-owned subsidiary post the successful completion of the acquisition.

                                        IDEXX's (IDXX) Catalyst Uptake Remains Strong & Boosts CAG

                                        Solid organic growth trend within IDEXX's (IDXX) CAG revenues to sustain on the back of a strong global placement of high-premium Catalyst instruments.

                                          Abbott Presents Positive Data for AMPLATZER Amulet Device

                                          Abbott (ABT) proceeds with initiatives to boost the core Structural Heart division.

                                            Merit Medical (MMSI) Up 18.9% in a Month on Solid Q1 Earnings

                                            Merit Medical (MMSI) reports strong Q1 earnings and sees solid growth across segments and geographies.

                                              Quality Systems (QSII) Q4 Earnings Beat, Bookings Rise Y/Y

                                              Quality Systems (QSII) exits fourth quarter on a solid note with a surge in bookings; issues a solid guidance for fiscal 2019.

                                                Abbott Presents Positive Study Results for Tendyne Device

                                                Abbott (ABT) leaves no stone unturned to drive its Structural Heart business.

                                                  Veeva Systems (VEEV) Beats Q1 Earnings Estimates, Raises View

                                                  Solid performance in Subscription revenues is a key catalyst for Veeva Systems (VEEV) in Q1.